Literature DB >> 627729

Antibody response and tumor growth in syngeneic mice immunized to partially purified B16 melanoma-associated antigens.

J C Bystryn.   

Abstract

Soluble murine melanoma-associated antigens (MAA), partially purified from the media of B16 melanoma cells in culture by ammonium sulfate precipitation and Sephadex G-200 chromatography, were tested for their effect on tumor growth. MAA were immunogenic in syngenic mice as evidenced by their ability to induce anti-melanoma antibodies and partial protective tumor immunity. The level of immunity was variable. It ranged from retardation of tumor development to almost complete suppression of tumor growth. The results were influenced by the nature of the control group, since immunization to either normal tissue antigens or complete Freund's adjuvant enhanced tumor growth. Overall, 46 of 91 MAA immunized mice, but none of 114 control mice, survived over 6 weeks (p less than 0.001). The protective immunity was specific since MAA immunized mice were not resistant to challenge with an unrelated syngeneic tumor (BW 10232 ADENOCARCINOMA). Partially purified normal tissue antigens were also immunogenic in syngeneic mice. They induced low levels of antibodies to, and enhanced the growth of, melanoma. These findings indicate that the culture media of melanoma cells contains tumor antigens that retain their biologic activity after partial purification, and that can induce specific, although only partial, protective immunity to melanoma.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 627729

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Characterization of a recombinant vaccinia virus expressing human melanoma-associated antigen p97.

Authors:  S L Hu; G D Plowman; P Sridhar; U S Stevenson; J P Brown; C D Estin
Journal:  J Virol       Date:  1988-01       Impact factor: 5.103

2.  Synthesis and expression of metastasis-associated, Met-72/83 antigens.

Authors:  J H Xiang; A K Kimura; J P Hansen
Journal:  Clin Exp Metastasis       Date:  1988 Nov-Dec       Impact factor: 5.150

Review 3.  Tumor vaccines.

Authors:  J C Bystryn
Journal:  Cancer Metastasis Rev       Date:  1990-07       Impact factor: 9.264

4.  Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model.

Authors:  Francesco Alessandrini; Laura Menotti; Elisa Avitabile; Irene Appolloni; Davide Ceresa; Daniela Marubbi; Gabriella Campadelli-Fiume; Paolo Malatesta
Journal:  Oncogene       Date:  2019-02-12       Impact factor: 9.867

5.  Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy.

Authors:  C D Estin; U S Stevenson; G D Plowman; S L Hu; P Sridhar; I Hellström; J P Brown; K E Hellström
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

6.  Immunohistological analysis of anti-melanoma host responses.

Authors:  R Strohal; K Marberger; H Pehamberger; G Stingl
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

7.  Recombinant BCG therapy suppresses melanoma tumor growth.

Authors:  R B Duda; H Yang; D D Dooley; G Abu-Jawdeh
Journal:  Ann Surg Oncol       Date:  1995-11       Impact factor: 5.344

8.  Host immunity to mycoplasma antigens introduced into B16 melanoma cells: effect on tumor growth rate and metastasis.

Authors:  C W Stackpole; A L Alterman; D M Fornabaio
Journal:  Clin Exp Metastasis       Date:  1988 Jul-Aug       Impact factor: 5.150

Review 9.  Animal models of human-derived cancer vaccines.

Authors:  D Herlyn; R Somasundaram; W Li; L Jacob
Journal:  Cell Biophys       Date:  1995-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.